ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AGY Allergy Therapeutics Plc

3.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.00 2.80 3.20 3.00 3.00 3.00 120,404 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 59.59M -43.07M -0.0090 -3.33 142.99M

Allergy Therapeutics PLC Hardman Research: Development across portfolio

05/04/2017 7:15am

RNS Non-Regulatory


TIDMAGY

Allergy Therapeutics PLC

05 April 2017

Hardman Research: Progressive development across portfolio

Progressive development across portfolio - AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a 'Named Patient' basis. Trials to obtain full approval as a biological have progressed well in EU with the first patient recruited in the pivotal birch pollen allergy vaccine Phase III trial. US trials are back on-track with a new safety trial underway. A Phase I study of Acarovac MPL, a 'dust mite allergy' vaccine, has been approved in Spain for 32 patients. Finally, Polyvac Peanut has completed pre-clinical testing and has potential to significantly disrupt the peanut allergy market.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/agy-interim-results-update-5th-april.pdf

 
 To contact us:      Contacts: 
  Hardman & Co        Dr Martin Hall 
  11/12 Tokenhouse    mh@hardmanandco.com 
  Yard                Dr Dorothea Hill 
  London              dmh@hardmanandco.com 
  EC2R 7AS            Dr Gregoire Pave 
                      gp@hardmanabdco.com 
                      Telephone: +44 20 7929 3399 
                      Follow us on Twitter @HardmanandCo 
 

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRABUGDSIUGBGRS

(END) Dow Jones Newswires

April 05, 2017 02:15 ET (06:15 GMT)

1 Year Allergy Therapeutics Chart

1 Year Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

Your Recent History

Delayed Upgrade Clock